Equity
Retained Earnings
Alnylam Pharmaceuticals Retained Earnings increased by 3.1% to -$6.50B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.6%, from -$7.35B to -$6.50B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows a downward trend with a 7.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
Metric ID:
retained_earningsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$4.98B | -$5.18B | -$5.44B | -$5.68B | -$5.96B | -$6.36B | -$6.57B | -$6.74B | -$7.02B | -$6.87B | -$7.01B | -$7.08B | -$7.09B | -$7.20B | -$7.29B | -$7.35B | -$7.41B | -$7.16B | -$6.70B | -$6.50B |
| QoQ Change | — | -4.1% | -5.0% | -4.4% | -4.9% | -6.8% | -3.3% | -2.7% | -4.1% | +2.1% | -2.0% | -0.9% | -0.2% | -1.6% | -1.2% | -0.8% | -0.9% | +3.4% | +6.4% | +3.1% |
| YoY Change | — | — | — | — | -19.7% | -22.8% | -20.8% | -18.8% | -17.9% | -8.0% | -6.7% | -4.9% | -1.0% | -4.8% | -4.0% | -3.8% | -4.5% | +0.6% | +8.0% | +11.6% |
Range-$7.41B – -$4.98B
CAGR+5.8%
Avg YoY Growth-7.3%
Median YoY Growth-4.9%
Current Streak3 quarters growth
Retained Earnings at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's retained earnings?
- Alnylam Pharmaceuticals (ALNY) reported retained earnings of -$6.50B in Q1 2026.
- How has Alnylam Pharmaceuticals's retained earnings changed year-over-year?
- Alnylam Pharmaceuticals's retained earnings increased by 11.6% year-over-year, from -$7.35B to -$6.50B.
- What is the long-term trend for Alnylam Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's retained earnings has grown at a 7.9% compound annual growth rate (CAGR), from -$4.59B to -$6.70B.